India's Intellectual Property Appellate Board (IPAB) has revoked the patent for global pharmaceutical company, GlaxoSmithKline's anti-cancer drug Tykerb. Tykerb (lapatinib) is a dual tyrosine ...
GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over $4 billion and potentially use the cash for Novartis' buy out deal. Bloomberg ...
GlaxoSmithKline Pharmaceuticals Ltd. (‘GSK India’) announces completion of its transaction with Novartis Healthcare Pvt. Ltd. ... GSK Pharma's Bengaluru facility to be operational by 2017 The ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.
The New England Journal of Medicine (NEJM) Images in Clinical Medicine article type captures and illuminates the sense of visual discovery and variety that physicians experience every day in ...
However, after the deal is completed at the end of 2019, by which time HUL will be India’s largest publicly-listed food and refreshments company, GSK plans to sell its stake in HUL in what is ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
(Reuters) - India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British ...
GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...